Embera Therapeutics

Embera Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for addiction and related disorders. The company's lead candidate, EMB-001, is a patented combination of two FDA-approved drugs, metyrapone and oxazepam, designed to modulate the stress response system to reduce cravings and prevent relapse. By targeting the hypothalamic-pituitary-adrenal (HPA) axis, Embera aims to address the physiological drivers of substance use disorders. The company is currently advancing clinical programs in cocaine use disorder and smoking cessation, with potential applications in binge eating disorder.